타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Blenrep (belantamab mafodotin) | Endoxan |
Overview Company | GSK | Celyad Oncology SA |
Overview Modality | ADC | ADC |
Overview Target | BCMA | Lymphoma, T-Cell, Peripheral |
Overview Indication | Multiple myeloma | Relapse/Refractory Multiple Myeloma |
Overview Phase | APPROVED | PHASE_2 |
Overview Status | DISCONTINUED | ACTIVE |
Overview Content status | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational |
Positioning Key differentiator | BCMA-targeted ADC with ocular AEs | — |
Positioning Known limitation | bypass this immune effector cell dependence, we developed a novel strategy using antibody-drug conjugates (ADCs) | — |
Technology Payload | MMAF | — |
Technology Linker | Non-cleavable | — |
MoA Mechanism | Belantamab mafodotin binds BCMA on plasma cells; afucosylated Fc enhances immune engagement while MMAF (microtubule inhibitor) payload is internalized and causes cell death. | Targeting Apoptosis Signaling Pathway |
MoA Biomarker | BCMA expression on myeloma cells. | biomarker for cancer metastasis |
Toxicology Species | Mouse, Rat | — |
Toxicology Animal (cat.) | Human | — |
Toxicology Major finding | Ocular toxicity (keratopathy, blurred vision) in majority of patients; thrombocytopenia and infusion reactions. | — |
Clinical Safety signal | Ocular toxicity (keratopathy, blurred vision) in majority of patients; thrombocytopenia and infusion reactions. | — |
Clinical Program phase | APPROVED | PHASE_2 |
Clinical Trial activity | No active/completed counts | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Blenrep (belantamab mafodotin) | Endoxan |
Overview Company | GSK | Celyad Oncology SA |
Overview Modality | ADC | ADC |
Overview Target | BCMA | Lymphoma, T-Cell, Peripheral |
Overview Indication | Multiple myeloma | Relapse/Refractory Multiple Myeloma |
Overview Phase | APPROVED | PHASE_2 |
Overview Status | DISCONTINUED | ACTIVE |
Overview Content status | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational |
Positioning Key differentiator | BCMA-targeted ADC with ocular AEs | — |
Positioning Known limitation | bypass this immune effector cell dependence, we developed a novel strategy using antibody-drug conjugates (ADCs) | — |
Technology Payload | MMAF | — |
Technology Linker | Non-cleavable | — |
MoA Mechanism | Belantamab mafodotin binds BCMA on plasma cells; afucosylated Fc enhances immune engagement while MMAF (microtubule inhibitor) payload is internalized and causes cell death. | Targeting Apoptosis Signaling Pathway |
MoA Biomarker | BCMA expression on myeloma cells. | biomarker for cancer metastasis |
Toxicology Species | Mouse, Rat | — |
Toxicology Animal (cat.) | Human | — |
Toxicology Major finding | Ocular toxicity (keratopathy, blurred vision) in majority of patients; thrombocytopenia and infusion reactions. | — |
Clinical Safety signal | Ocular toxicity (keratopathy, blurred vision) in majority of patients; thrombocytopenia and infusion reactions. | — |
Clinical Program phase | APPROVED | PHASE_2 |
Clinical Trial activity | No active/completed counts | No active/completed counts |
추천 비교
추천 비교